ASHP InterSections ASHP InterSections

April 16, 2020

New ASHP Resources and Efforts to Help You Combat COVID-19

Dear Colleagues,

Paul W. Abramowitz, Pharm.D., Sc.D. (Hon.), FASHP

ASHP CONTINUES TO WORK ACROSS MULTIPLE FRONTS to help our members and all healthcare professionals to address the COVID-19 pandemic. We have intensified our advocacy efforts and continue to create new and timely resources to ensure that you are prepared to meet the demands of this sustained public health crisis.

Based on concerns expressed by ASHP members who are on the front lines of the COVID-19 pandemic, I’ve had calls with a wide array of industry stakeholders, including wholesalers, about ways to help ensure that providers have the medications they need to treat their patients. Please continue to let us know of challenges you may be facing related to COVID-19, and we will work to do everything we can to help address them at the national level.

To that end, today, we launched a new COVID-19 microsite to better organize our resources and optimize access for those who need them. The microsite features content for pharmacists and other healthcare providers in key areas, including patient care, infection prevention, policy and advocacy, and more. We will continue to enhance the site with new and updated content, which remains open to all professionals who are engaged in the COVID-19 response.

A critical focus of our continued support remains facilitating real-time information sharing among pharmacists, including those in the current epicenters, to help ongoing response efforts and prepare areas where the peak of the pandemic is yet to come.

In response to the COVID-19 pandemic, we have accelerated production on our popular @ASHPOfficial podcast, moving to a daily release schedule. We have produced 20 episodes to date dedicated to COVID-19 on topics that include managing drug shortages, evaluating the scientific literature, and ethical considerations. Last week, a member let us know that information from an @ASHPOfficial podcast helped her to change treatment protocols for patients at her long-term care facility, potentially saving many lives. I encourage you to subscribe to @ASHPOfficial to receive this free, timely content that includes credible information, best practices, and important experiences from your peers who are working on the front lines of the pandemic.

We have also recently launched a free webinar series dedicated to COVID-19 response. Tomorrow’s live webinar describes how New York’s Mount Sinai Health System and Montefiore Health System responded to their COVID-19 patient surge, and the coordinated efforts of New York City’s pharmacy leadership to support hospitals and health systems. Please be on the lookout for new webinars each week that will provide valuable perspective and intelligence on how pharmacists in varied settings are responding to the pandemic.

Our COVID-19 Connect Community has become a robust venue for discussion and information sharing among pharmacists. There are more than 52,000 community members actively engaged in 800 different discussion threads covering a range of topics. ASHP is also using this platform to help inform our efforts to develop and deliver crucial resources to assist those on the front lines.

I would also like to make you aware of another new initiative launched this week by ASHP. The Pharmacy Executive Leadership AllianceTM – or PELATM – was created for chief pharmacy officers and multi-hospital system pharmacy executive leaders who face distinct challenges working within highly complex, vertically and horizontally integrated networks and multi-hospital health systems.

PELA will leverage ASHP’s resources for information exchange on issues unique to this executive-level group. PELA participants will gain valuable insights on market trends and innovations for advancing medication use that is always optimal, safe, and effective for all people across our nation’s complex health networks. Key areas of focus will include health-system-wide integration of digital and telehealth, effective enterprise revenue cycle management, strategies for addressing industry disrupters, optimization of horizontal and vertical integration, and new technologies and science. Emerging issues related to COVID-19 business recovery will also be addressed.

Although ASHP has been planning the launch of PELA for some time, the unprecedented demands of the COVID-19 pandemic underscore the importance of providing opportunities to connect and share critical information for pharmacy executives. I look forward to sharing more information about this exciting initiative, as well as relevant outputs from the group, with our members in the future.

Finally, I wanted to share some news from the advocacy front. This week, the Drug Enforcement Administration (DEA) announced flexibilities for satellite hospitals or clinics as a result of COVID-19. During the national emergency, DEA will allow a DEA-registered hospital or clinic to handle controlled substances at a satellite hospital or clinic location under the organization’s current registrations. DEA is relaxing limits on the distribution of controlled substances between practitioners. Under the new flexibility, registered practitioners can distribute or dispense more than 5% of their total doses to another registered practitioner without registering as a distributor. Practically speaking, this will better enable health systems and hospitals to get controlled substances where they are most needed. DEA is also allowing distributors to ship controlled substances directly to these satellite hospitals or clinics. This is a significant change for many of our members who use additional satellite hospital and clinic locations to accommodate the large influx of COVID-19 patients presenting for treatment. Having these flexibilities will allow our members to more effectively treat their patients.

I am also pleased to note that, at the urging of ASHP and its members, USP has issued “Operational Considerations for Sterile Compounding During COVID-19 Pandemic,” a new document that supports risk-based enforcement discretion of compounding standards. The document addresses the assignment of beyond-use dates and considerations for certification and recertification of engineering controls, and reinforces CDC recommendations for cleaning and disinfecting a facility when someone is ill.

On Tuesday, ASHP, the American Pharmacists Association, and the National Community Pharmacists Association authored a letter to New York Sen. Chuck Schumer thanking him for recognizing pharmacists as providers of essential patient care services and asking him to support pharmacists’ critical role as frontline healthcare providers during the COVID-19 pandemic. ASHP will continue to work with Sen. Schumer and others to recognize the vital patient care role of pharmacists and to support the proposed Heroes Fund legislation that provides premium pay for essential front line workers – including pharmacists – during this current public health crisis, and we will continue our broader efforts to advocate for expanded patient access to pharmacist services.

In closing, please know that we remain committed to supporting you by providing robust, timely, and relevant resources to assist you in your practice, to advocate on your behalf, and to help you focus on your own health and well-being during this ongoing public health emergency.

Thank you for being a member of ASHP and for everything that you do for your patients and our profession.

Sincerely,

Paul

 

April 9, 2020

Important Wins on the Advocacy Front in the Fight Against COVID-19

Dear Colleagues,

Paul W. Abramowitz, Pharm.D., Sc.D. (Hon.), FASHP

AS THE IMPACT OF THE COVID-19 PANDEMIC CONTINUES TO ESCALATE ACROSS THE COUNTRY, there is increased urgency to ensure that frontline pharmacists, pharmacy technicians, and our healthcare partners have the medications and equipment they need to successfully treat their patients. ASHP continues to spearhead multiple advocacy efforts that support your ability to provide the best care possible for those in need.

Mitigating shortages of critical medications like propofol, fentanyl, midazolam, paralytics, and others remains a high priority. We continue to engage with relevant federal agencies to improve access to medications. I am pleased to report that the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA) have taken critical actions in direct response to ASHP’s advocacy efforts.

ASHP, in coordination with the American Medical Association, the American Hospital Association, the Association for Clinical Oncology, and the American Society of Anesthesiologists, sent a letter last week to the DEA requesting an immediate increase in the annual production quota allocations for Schedule II controlled substances. This would enable manufacturers and 503B outsourcing facilities to increase the supply of opioids critical to the care of COVID-19 patients on ventilators. As a direct result of this collaborative advocacy effort, the DEA announced yesterday that it is taking immediate actions to address this critical issue. These actions include increasing the annual production quota for controlled substances, including fentanyl, morphine, and hydromorphone, that are used for the treatment of mechanically ventilated COVID-19 patients, and increasing the amount of ketamine, diazepam, and other controlled substances that can be imported into the United States.

We also sent a letter to the FDA advocating for regulatory flexibility in compounding drugs in shortage and compounding in hospitals. ASHP’s advocacy efforts, including significant staff engagement on the issue, directly triggered the FDA to clarify existing compounding guidance, including the removal of the one-mile radius requirement for hospitals compounding medications. FDA’s quick action to reduce regulatory hurdles for health systems is an important step to help clarify compounding guidance during this crisis.

ASHP will continue to advocate for additional compounding flexibility, including the expansion of FDA’s drug shortage list to include products ASHP has identified as in shortage. We will also continue to seek 503B outsourcing facility flexibility, particularly for hospital-owned or affiliated 503B operations, to help ensure they can meet hospitals’ medication needs.

Yesterday, we were pleased to see that the Department of Health and Human Services (HHS) authorized pharmacists to order and administer COVID-19 tests pursuant to the Public Readiness and Emergency Preparedness (PREP) Act. The authorization is responsive to the joint COVID-19 recommendations we created with other national organizations. While this authorization does not address pharmacist reimbursement, we are encouraged to see HHS providing pharmacists with a greater role in supporting the COVID-19 response, and we continue to work on that issue.

We also continue to actively advocate for Congress to recognize pharmacists as providers in the Medicare program to further support the COVID-19 response and beyond. Yesterday, ASHP and 11 other national organizations sent a letter requesting that Congress immediately support legislation that would establish pharmacists as providers in Medicare Part B on an emergency basis to provide COVID-19 and flu testing. This authority is an important step in being able to rapidly expand access to testing across our country to support the national response to this crisis. We also see this as a step toward expanded recognition of pharmacists by payers, including Medicare.

Finally, ASHP is also working with our members and other stakeholders to gain access to medications from the Strategic National Stockpile (SNS). Most recently, we joined with several organizations to request that FEMA immediately release all available quantities of a number of critical drugs from the SNS to the New York and New Jersey Departments of Health to address urgent patient care needs. We are also working to support other state affiliates and members across the country with these important requests.

ASHP and its government relations team will continue to work tirelessly with our collaborating partners to ensure that U.S. regulatory authorities are responding to the current needs of pharmacists and healthcare providers.

While our collective attention is on the needs of frontline practitioners, I wanted to take an opportunity to highlight some positive news about the newest members of our profession. ASHP’s 2020 Residency Match concluded this week, and I want to congratulate the 5,269 future pharmacists who matched with 2,551 PGY1 and PGY2 pharmacy residency programs across the country. This number represents a 46% increase in the number of available positions over the past five years – a remarkable rate of growth. I am pleased that our accredited residency programs have demonstrated an outstanding commitment to training during the pandemic. While managing multiple critical priorities, these programs continued to interview applicants virtually. This undoubtedly will be a unique time during which to begin a residency program regardless of its focus. ASHP is committed to ensuring that these young practitioners and their programs have the needed resources to successfully conduct critically important resident training this year and beyond.

In the same vein, please know that ASHP stands ready to offer you and your healthcare colleagues that same level of steadfast support. In addition to advocating to give you access to critical medications, ASHP continues to update and create new resources and tools that can be found on our COVID-19 Resource Center. We have also opened access to many evidence-based online resources and tools on ashp.org, making them widely available to all pharmacists and the broader healthcare community.

Over the last few weeks, I have heard countless stories from members and others about the challenges they are facing, but I’ve also heard many stories of hope and heroism. I, and David Chen, ASHP assistant vice president for Pharmacy Leadership and Planning, have listened in on calls from pharmacy leaders at major health systems in New York City, the pandemic’s current epicenter. We are incredibly impressed by how these leaders have shared their information and experiences and how they support each other and their frontline staff. This is a tremendous example of how peer-to-peer connection and communication can aid in the pandemic response. Their experiences and willingness to share their stories will undoubtedly help others in responding to COVID-19 in facilities across the country. We applaud them for these efforts.

Please also know that ASHP is here to support your well-being, which should remain a priority for all healthcare personnel during this challenging time. Please make sure that you are taking care of yourself and your family.

“ASHP has our backs.” These are the words of a member who recently reached out to us. This really resonated with me, and I can assure you that we will continue to work across all fronts, leveraging our talented staff, our valued partners, and our amazing members to provide you with the information, connections, and resources you need today and in the future.

Thank you for everything you do for your patients and the profession.

Sincerely,

Paul

Powered by WordPress